Axcess™ Oral Delivery System


The Axcess™ delivery system significantly increases the absorption of peptides, proteins and other macromolecules across the intestinal wall when delivered orally without any chemical modification of the active compounds.


The Axcess™ delivery system is based on a simple mixture of components consisting entirely of registered pharmacopoeial or GRAS excipients with a long history of pharmaceutical use. The absorption enhancing activities obtained from the formulation of these excipients is entirely novel and is covered by five international patent families.


Core patents have been granted in major territories including the US, Europe, Japan, Korea, China, India, Russia, among others.


Diabetology has licensed the exclusive rights to Axcess™ for the formulation of its specific development and out-licensing programs.


Additionally, the Axcess™ delivery system may allow Diabetology to further expand its pipeline in the future with the development of new oral therapies for diabetes.

How Does it Work?

  • Enteric coated capsule protects API in its passage past the stomach


  • Enteric coating dissolves on rise in pH and releases formulation into lumen of small intestine


  • Axcess excipients protect API from degradation by transiently inhibiting gut proteases


  • Then enhance uptake by increasing transcellular delivery


  • Absorption occurs in jejunum and upper small intestine


  • Transfers into the mesenteric portal system, drains to the liver



Please See Animation Below


Our oral delivery technology can be applied to a broad range of APIs and we can enter into strategic partnerships and collaborative product development arrangements 

Print | Sitemap
© 2021, Diabetology Ltd | Privacy Policy | Terms & Conditions | Copyright